# Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

> **NCT02296684** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 67 (actual)

## Conditions studied

- Cancer of Head and Neck
- Head and Neck Cancer
- Neoplasms, Head and Neck
- Carcinoma, Squamous Cell of Head and Neck
- Squamous Cell Carcinoma of the Head and Neck
- Squamous Cell Carcinoma, Head and Neck

## Interventions

- **BIOLOGICAL:** MK-3475 (neoadjuvant)
- **PROCEDURE:** Surgery
- **RADIATION:** Intensity modulated radiation therapy
- **RADIATION:** Image-guided radiation therapy
- **DRUG:** Cisplatin
- **BIOLOGICAL:** MK-3475 (adjuvant)
- **PROCEDURE:** Peripheral blood

## Key facts

- **NCT ID:** NCT02296684
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-25
- **Primary completion:** 2022-04-05
- **Final completion:** 2025-07-21
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296684, "Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT02296684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*